Cardiovascular Drugs Market to reach USD 63.96 Billion by 2026; Growing Need for Advanced and Effective Drugs to Propel Growth, says Fortune Business Insights

Key Companies Covered in the Cardiovascular Drugs Market Research Report are Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, among others.


Pune, Nov. 26, 2019 (GLOBE NEWSWIRE) -- The global Cardiovascular Drugs Market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth of the Cardiovascular Drugs Market. According to the American Heart Association, Cardiovascular disease (CVD) accounted for 840,678 deaths in the US in 2016, approximately 1 of every 3 deaths. Also, between 2013 and 2016, 121.5 million American adults had some form of cardiovascular disease. These Cardiovascular Drugs Market trends, along with the innovation and development of new drugs, will foster the growth of the market. Moreover, In 2014, a study was conducted by the American Heart Association, cardiovascular disease accounted for more than 17.6 million deaths per year in 2016 and is likely to grow to more than 23.6 million by 2030.

As per the report, published by Fortune Business Insights, titled “Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), By Disease Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026” the market was at USD 47.29 billion in 2018. The report offers dynamic insights into the global Cardiovascular Drugs Market, covering growth prospects, market development potential, supply and demand, profitability, and other important aspects. It is considered to be reliable source of information along with the data on the market trends. The researchers and analysts have prepared it with an advanced research methodology and authentic primary and secondary sources of market statistics and data. Readers are provided with a clear understanding of the current and future situations of the market based on revenue,  shares, trends, technology, advancements and innovations, prevailing factors and restricting factors.

To Gain More Insights into the Market with Detailed Table of Content and Figures, Click Here

Growing Need for Advanced and Effective Drugs to Propel Growth

The increasing demand for effective drugs and therapy is expected to aid the growth of the market.  The rising R&D investment for innovative drugs and cardiovascular therapeutics will further accelerate the growth of the market. The launch of novel therapies by key players is likely to create growth opportunities for the market. For instance, Novartis AG and Blackstone’s Life Sciences announced the launch of Anthos Therapeutics for the development of cardiovascular drugs as there are large unmet needs for next-generation anti-thrombotic therapies in patients.

New Product Launches will Propel Growth

India based Natco Pharma announced the launch of the generic version of valsartan-sacubitril, a cardiovascular drug for the treatment of congestive heart failure. Novartis AG holds the patent in India for valsartan-sacubitril called Vymada. The launch of the new drug will create growth opportunities for the market in the foreseeable future. Furthermore, increasing awareness regarding cardiovascular health and the surge in product launches will boost Cardiovascular Drugs Market growth. The introduction of several advanced drugs addressing the diverse treatment needs of cardiovascular diseases will further bolster the growth of the market. For instance, Bristol-Myers Squibb Company and Pfizer Inc. introduced a cardiovascular drug called Eliquis (apixaban), which now has the highest sales and is demonstrated to be superior in terms of risk reductions compared to other drugs in the market.

Sample PDF

Some of the Major Companies Present in the Global Cardiovascular Drugs Market Include:

  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Others

Speak to Analyst

Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Major Cardiovascular Diseases by Key Countries
    • Pipeline Analysis
    • Key Industry Developments Such as Mergers & Acquisitions
    • New Product Launches
    • The Regulatory Scenario in Key Countries
    • Reimbursement Scenario by Key Countries
    • Advances in R&D for Novel Therapeutics
  • Global Cardiovascular Drugs Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Drug Type
      • Antihypertensive
      • Antihyperlipidemic
      • Anticoagulants
      • Antiplatelet Drugs
      • Others
    • Market Analysis, Insights and Forecast – By Disease Indication
      • Hypertension
      • Hyperlipidemia
      • Coronary Artery Disease
      • Arrhythmia
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
  • Competitive Landscape
  • Strategic Recommendations


Request for Customization:

Browse Related Reports:

Cardiometabolic Disease Market Size, Share and Global Trend By Treatment (Angiotensin-converting Enzyme (ace) Inhibitors, Diuretics, Glucophage), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Geography Forecast till 2026

Cardiovascular Stents Market Size, Share and Industry Analysis By Product Type (Coronary Stenting, Peripheral Stenting), Stent Type (Drug Eluting Stents (DES), Bioresorbable Stents, Bare Metal Stents & Others), Disease Indication (Venous Disease, Arterial Disease), End User and Regional Forecast, 2018 - 2025

Coronary Stents Market Size, Share and Industry Analysis By Deployment (Self and Balloon-expandable), Stent Type (Drug Eluting Stent, Bioresorbable Stent, Bare Metal Stent, Covered Stent and Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Catheterization Labs), and Regional Forecast 2018-2025

Orphan Drugs Market Size, Share and Industry Analysis By Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Regional Forecast, 2018 - 2025

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. 

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact us:
Fortune Business Insights Pvt. Ltd. 
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245